NASDAQ:VRTX

Vertex Pharmaceuticals Stock News

etoro logo Buy VRTX
*Your capital is at risk
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
These two biotechs are flying high right now.
Boosted by demand among the best mutual funds and an FDA approval, AbbVie shows strength in ailing market. The post FDA Approval, Top Funds Lift Drugmaker In Ailing Market appeared first on Investor's

5 Unstoppable Trends to Invest $5,000 in for 2023

05:52am, Thursday, 29'th Dec 2022
These trends won't fade away, and some of the companies that are positioned to ride them should be big winners.
CF product revenues grew by 18% in Q3 of 2022 to $2.33 billion. TRIKAFTA continues uptake in the U.S. but larger 49% sales growth was observed in territories outside of the U.S. VX-522 is being develo

Is Vertex Pharmaceuticals a Buy?

06:15am, Tuesday, 27'th Dec 2022
There's more growth ahead for this biotech giant.
They have what it takes to deliver growth over time.
This company has had a solid year, but there is still plenty of work ahead.
For many investors, now would be an opportune time to take advantage of great stocks trading at a discount.
Vertex revenue grew 18% y/y in Q3 2022. The robust pipeline propels Vertex beyond the cystic fibrosis market.
Expect a bigger, more diversified, and more entrenched entity to emerge over the coming years.
These stocks have climbed by double digits this year.
Both stocks are heading for double-digit gains this year.
The momentum for these high-flying stocks should continue in the new year.
Stocks usually go down during recessions, but long-term investors can still come out on top.
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE